Sheela J. Huff

Receipt date: 06/11/2009

AC/TMH:mjw:csw 06/11/09 4239-67016-02 1072060 E-289-2002/0-US-03

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

U.S. PATENT DOCUMENTS

Examiner Name

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending provided the publication provided to the publication of the publication of the publication of the publication date. For unpublished pending provided to the publication of the publication of the publication date.

Examiner's Initials*	Cite No. (optional)	Number	Date	Name of Applicant or Patentee
/S.H./		6,855,507	02/15/2005	Chugai Seiyaku Kabushiki Kaisha

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Date	Name of Applicant or Patentee
/S.H./		JP	11-201967	01/14/1998	Chugai Pharmaceutical Co. Ltd.
/S.H./		WIPO	99/40220	08/12/1999	Glaxo Group Limited
/S.H./		WIPO	01/16604	03/08/2001	Signal Pharmaceuticals, Inc.
/S.H./		WIPO	01/74404	10/11/2001	Novarx
***************************************		JP	2002-506613	03/05/2002	Glaxo Group Limited
		Îb	2003-508755	03/04/2003	Signal Pharmaceuticals, Inc.
		JP	2003-528930	09/30/2003	Novarx

EXAMINER SIGNATURE:	/Sheela Huff/	DATE CONSIDERED:	08/19/2009		
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not					

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.